All In Biotech

Drug Trial Radar · NCT00559585

Methotrexate-Inadequate Response Study

A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate

Last checked: Nov 20, 2026Latest source record: Nov 9, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,492 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,492

Actual

Start

Jan 2008

Primary completion

Nov 2009

Study completion Sep 2014

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 16, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

  • Subcutaneous (SC) AbataceptDrug

    Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.

  • Intravenous (IV) AbataceptDrug

    Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo). 500mg (for body weight up to 60 kg) 750 mg (body weight between 61 and 100 kg) 1g (body weight above 100 kg)infusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169Time frame: Day 169
  2. Anti-TNF Failure Sub-Study Double Blind Period : Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Response in Anti-TNF Failure PopulationTime frame: Days 85, and 169 and postvisits on Days 28, 56, and 85

Locations

203 sites in 24 countries. Site status is shown where the registry gives one.

  • Rheumatology Associates, Pc

    Birmingham, Alabama

  • Coastal Clinical Research, Inc

    Mobile, Alabama

  • Advanced Arthritis Care & Research

    Scottsdale, Arizona

  • Catalina Pointe Clinical Research, Inc.

    Tucson, Arizona

  • St. Joseph'S Mercy Clinic

    Hot Springs, Arkansas

  • Talbert Medical Group

    Huntington Beach, California

  • Allergy & Rheumatology Medical Clinic, Inc.

    La Jolla, California

  • Valerius Medical Group &Research Ctr. Of Greater Long Beach

    Long Beach, California

  • Stanford University School Of Medicine

    Palo Alto, California

  • San Diego Arthritis Medical Clinic

    San Diego, California

  • Boulder Medical Center

    Boulder, Colorado

  • Arthritis Assoc And Osteo Ctr Of Col Sprgs

    Colorado Springs, Colorado

  • Denver Arthritis Clinic

    Denver, Colorado

  • Arthritis Center Of The Rockies, Pc

    Loveland, Colorado

  • Guadagnoli, Germano

    Bridgeport, Connecticut

  • Joao Nascimento

    Bridgeport, Connecticut

  • Clinical Research Center Of Ct/Ny

    Danbury, Connecticut

  • Arthritis And Rheumatic Disease Specialties

    Aventura, Florida

  • Arthritis & Osteoporosis Treatment Center, Pa

    Orange Park, Florida

  • Rheumatology Associates Of Central Florida

    Orlando, Florida

  • The Arthritis Center

    Palm Harbor, Florida

  • Sarasota Arthritis Research Center

    Sarasota, Florida

  • Arthritis & Rheumatology Of Georgia,Pc

    Atlanta, Georgia

  • Boise Rheumatology/ Intermountain Research Center, Inc

    Boise, Idaho

  • Coeur D'Alene Arthrit Clin

    Coeur d'Alene, Idaho

  • Quincy Medical Group

    Quincy, Illinois

  • Rockford Orthopedic Associates, Ltd.

    Rockford, Illinois

  • The Arthritis Center

    Springfield, Illinois

  • Klein And Associates, M.D., Pa

    Cumberland, Maryland

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts

  • Shores Rheumatology, P. C.

    Saint Clair Shores, Michigan

  • Arthritis Assoicates Of Mississippi

    Jackson, Mississippi

  • Kansas City Internal Medicine

    Lee's Summit, Missouri

  • Physician Research Collaboration, Llc

    Lincoln, Nebraska

  • Allergy And Arthritis Associates

    Dover, New Jersey

  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico

  • Albuquerque Rehabilitation & Rheumatology Pc

    Albuquerque, New Mexico

  • The Center For Rheumatology, Llp

    Albany, New York

  • Southern Tier Arthritis & Rheumatism

    Olean, New York

  • Arthritis Health Associates

    Syracuse, New York

Showing 40 of 203 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.